SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Newron Pharmaceuticals: Completion of Patient Enrollment in MOTION, a Phase III Pivotal Clinical Trial of Safinamide in Early Parkinson's Disease